Evidence map›Paper›PMID 26364608›Full record

ArticleOncogene2016

Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.

C Coarfa, W Fiskus, V K Eedunuri, K Rajapakshe, C Foley, S A Chew, S S Shah, C Geng, J Shou, J S Mohamed and 2 more

Open access · greenAbstract readComparative Study
In one paragraph

Article in Oncogene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 82 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Preliminary study on miRNA in prostate cancer.World journal of surgical oncology · 2023
    Article
  9. miR-125b-5p, miR-155-3p, and miR-214-5p and TargetInternational journal of molecular sciences · 2023
    Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Role of miRNA-145, 148, and 185 and Stem Cells in Prostate Cancer.International journal of molecular sciences · 2022
    Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

C CoarfaDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
W FiskusDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
V K EedunuriAdrienne Helis Malvin Medical Research Foundation, New Orleans, LA, USA.
K RajapaksheDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
C FoleyDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
S A ChewDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
S S ShahDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
C GengDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
J ShouDepartment of Medicine, Baylor College of Medicine, Houston, TX, USA.
J S MohamedDepartment of Medicine, Baylor College of Medicine, Houston, TX, USA.
B W O'MalleyDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
N MitsiadesDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Baylor College of Medicine · USChildren's Cancer Center · US

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9M
REPRODUCTIVE HORMONES: BIOLOGICAL AND MOLECULAR ACTIONSR01HD008188 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI DAVID M LONARD, JOHN P LYDON · 1985 to 2026
$16.3M
Diabetes Endocrinology Research CenterP30DK079638 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI CHAN, LAWRENCE · 2008 to 2012
$6.4M
NCI NIH HHS P30 CA125123NICHD NIH HHS R01 HD008188NIDDK NIH HHS P30 DK079638
6 · The paper itself

Abstract

MicroRNAs are important epigenetic regulators of protein expression by triggering degradation of target mRNAs and/or inhibiting their translation. Dysregulation of microRNA expression has been reported in several cancers, including prostate cancer (PC). We comprehensively characterized the proteomic footprint of a panel of 12 microRNAs that are potently suppressed in metastatic PC (SiM-miRNAs: miR-1, miR-133a, miR-133b, miR-135a, miR-143-3p, miR-145-3p, miR-205, miR-221-3p, miR-221-5p, miR-222-3p, miR-24-1-5p, and miR-31) using reverse-phase proteomic arrays. Re-expression of these SiM-miRNAs in PC cells suppressed cell proliferation and targeted key oncogenic pathways, including cell cycle, apoptosis, Akt/mammalian target of rapamycin signaling, metastasis and the androgen receptor (AR) axis. However, only 12%, at most, of these observed protein expression changes could be explained by predicted direct binding of miRNAs to corresponding mRNAs, suggesting that the majority of these proteomic effects result indirectly. AR and its steroid receptor coactivators (SRCs; SRC-1, -2 and -3) were recurrently affected by these SiM-miRNAs. In agreement, we identified inverse correlations between expression of these SiM-miRNAs and early clinical recurrence, as well as with AR transcriptional activity in human PC tissues. We also identified robust induction of miR-135a by androgen and strong direct binding of AR to the miR-135a locus. As miR-135a potently suppresses AR expression, this results in a negative feedback loop that suppresses AR protein expression in an androgen-dependent manner, while de-repressing AR expression upon androgen deprivation. Our results demonstrate that epigenetic silencing of these SiM-miRNAs can result in increased AR axis activity and cell proliferation, thus contributing to disease progression. We further demonstrate that a negative feedback loop involving miR-135a can restore AR expression under androgen-deprivation conditions, thus contributing to the upregulation of AR protein expression in castration-resistant PC. Finally, our unbiased proteomic profiling demonstrates that the majority of actual protein expression changes induced by SiM-miRNAs cannot be explained based on predicted direct interactions.

Indexed as

ProteomicsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticGene SilencingHumansMaleMicroRNAsNeoplasm MetastasisPrognosisProstatic Neoplasms, Castration-ResistantReceptors, AndrogenSignal TransductionUp-RegulationAR protein, humanMicroRNAsReceptors, Androgen

Identifiers

PMID26364608
PMCPMC5915337
OpenAlexW1422310337

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.